Relafen 750, this medication , represents a noteworthy advancement to biochemical pharmacology , offering a distinct mechanism for activity . This primary impact is to inhibit prostaglandin synthesis , specifically targeting COX-2 . This targeted inhibition provides symptom management and potentially reducing the bowel chance associated with conven